摘要
目的观察脑苷激肽治疗糖尿病周围神经病变的疗效。方法175例糖尿病周围神经病变患者分为常规治疗组45例,脑苷激肽治疗组75例,弥可保对照组50例。常规治疗组予饮食控制、降糖、降压、调脂、抑制血小板聚集、扩管改善微循环、应用维生素B1、B6等治疗,脑苷激肽、对照组在常规治疗的基础上分别用脑苷激肽40mg、弥可保500μg静点,疗程均为3周。结果3组患者起效时间差异无显著性意义(P>0.05)。3组患者中对称性多发性周围神经病变疗效间差异有显著性意义(P<0.01),且观察组、对照组与常规组间差异均有显著性意义(P<0.05)。结论脑苷激肽在治疗糖尿病周围神经病变上有与弥可保相似的确切疗效。
Objective The efficacy of ganglioside GM1 in the treatment of the diabetic peripheral neuropathy was studied by compared with mecobalamin. Methods 175 cases with diabetic peripheral neuropathy were divided into three groups： the ordinary treatment group of 45 cases, the GM1 group of 75cases, and mecobalamin group of 50 cases. The ordinary treatment group was treated with diet controlling, dropping of blood sugar and blood pressure, regulating hyperlipeidemia, inhabiting patelet aggregation, using VitB1 and V itB12 etc. on the basis of the ordinary treatment, the GM1 group was treated with 40mg introvenus dripping every day, and the mecobalamin group was treated with mecobalamin 500μg introvenus dripping , the course of treatment was three weeks. Results After three weeks treatment, the total effective rates of the three groups were 85.5%, 96.5%, 95. 0% respectively. There was no statistic difference between GM1 and mecobalamin groups. Conclusion We can get the conclusion that GM1 and mecobalamin have almost the same effect in the treatment of the diabetic peripheral neuropathy.
出处
《实用心脑肺血管病杂志》
2006年第8期639-640,共2页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
脑苷激肽
糖尿病
神经病变
Ganglioside GM1
Diabetic
Neuropathies
